Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experience

Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naïve patients: A single-centre experience

Objectives: Transmitted drug resistance (TDR) and HIV-1 genetic diversity may affect treatment efficacy and clinical outcomes. Here we describe the circulating viral subtypes and estimate the prevalence of drug resistance among antiretroviral therapy (ART)-naïve patients attending Sapienza Universit...

Full description

Bibliographic Details
Main Authors:	Laura Mazzuti, Taulant Melengu, Francesca Falasca, Marianna Calabretto, Eleonora Cella, Massimo Ciccozzi, Ivano Mezzaroma, Giancarlo Iaiani, Martina Spaziante, Gabriella d’Ettorre, Caterina Fimiani, Vincenzo Vullo, Guido Antonelli, Ombretta Turriziani
Format:	Article
Language:	English
Published:	Elsevier 2020-03-01
Series:	Journal of Global Antimicrobial Resistance
Subjects:	Drug resistance mutation Transmitted drug resistance Antiretroviral-naïve HIV-1 subtype Integrase inhibitor resistance
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213716519302309

Similar Items

Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?
by: Mark eWainberg, et al.
Published: (2015-04-01)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
by: Linda A. Mandikiyana Chirimuta, et al.
Published: (2022-10-01)

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland
by: Parczewski Miłosz, et al.
Published: (2012-12-01)

The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004
by: Hanping Li, et al.
Published: (2016-10-01)

Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
by: Kirsten L. White, et al.
Published: (2014-07-01)

A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
by: Collins C. Iwuji, et al.
Published: (2020-07-01)

Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice—A Refined Approach in the COVID-19 Era
by: Valeria Cento, et al.
Published: (2021-04-01)

Doravirine-associated resistance mutations in antiretroviral therapy naïve and experienced adults with HIV-1 subtype C infection in Botswana
by: Ontlametse T. Bareng, et al.
Published: (2022-12-01)

HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients
by: Elmi Abar Aden, et al.
Published: (2012-10-01)

Transmitted drug resistance among HIV-1 drug-naïve patients in Greece
by: Maria Kantzanou, et al.
Published: (2021-04-01)

Trends in HIV-1 pretreatment drug resistance and HIV-1 variant dynamics among antiretroviral therapy-naive Ethiopians from 2003 to 2018: a pooled sequence analysis
by: Mulugeta Kiros, et al.
Published: (2023-10-01)

Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART
by: Helene Mens, et al.
Published: (2022-06-01)

Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County
by: William Chan, et al.
Published: (2019-09-01)

HIV-1 Drug Resistance Detected by Next-Generation Sequencing among ART-Naïve Individuals: A Systematic Review and Meta-Analysis
by: Fei Ouyang, et al.
Published: (2024-02-01)

Comprehensive Analysis of HIV-1 Integrase Resistance-Related Mutations in African Countries
by: Francesco Branda, et al.
Published: (2024-01-01)

Drug-selective pressure effect on HIV integrase mutations in antiretroviral naïve and experienced patients
by: Parya Basimi, et al.
Published: (2023-04-01)

No transmitted drug resistance to HIV integrase strand-transfer inhibitors after their scale-up in Estonia in 2017
by: Arina Šablinskaja, et al.
Published: (2023-06-01)

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients
by: Massimiliano Fabbiani, et al.
Published: (2023-05-01)

Drug Resistance to Integrase Strand-Transfer Inhibitors among HIV-1-Infected Adults in Guangdong, China
by: Yun Lan, et al.
Published: (2022-11-01)

HIV drug resistance and HIV transmission risk factors among newly diagnosed individuals in Southwest China
by: Xianwu Pang, et al.
Published: (2021-02-01)

Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency
by: Sophie M. Bastarache, et al.
Published: (2014-09-01)

First report of computational protein–ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients
by: Farzane Ghasabi, et al.
Published: (2022-07-01)

HIV-1 Drug Resistance among Treatment-Naïve Patients in Russia: Analysis of the National Database, 2006–2022
by: Alina Kirichenko, et al.
Published: (2023-04-01)

Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999–2014
by: Annette M. Aldous, et al.
Published: (2017-09-01)

Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan
by: Ya-Wei Weng, et al.
Published: (2019-08-01)

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study
by: Aurelio Orta-Resendiz, et al.
Published: (2020-02-01)

Detection of human immunodeficiency virus type 1 transmitted drug resistance among treatment-naive individuals residing in Jakarta, Indonesia
by: Siti Qamariyah Khairunisa, et al.
Published: (2020-07-01)

Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Baoding, Hebei province, China
by: Weiguang Fan, et al.
Published: (2022-09-01)

Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs
by: Bluma G. Brenner, et al.
Published: (2010-11-01)

Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors
by: Karolin Meixenberger, et al.
Published: (2017-11-01)

Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naïve HIV-1-Infected Adults in Guangdong Province, China, in 2018
by: Lan Y, et al.
Published: (2020-12-01)

Analysis of ART effects and drug resistance in adult HIV/AIDS patients in Meigu County, Liangshan Prefecture, China
by: Li Yuan, et al.
Published: (2024-02-01)

Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries
by: Richard M. Gibson, et al.
Published: (2017-12-01)

High prevalence of HIV-1 transmitted drug resistance among therapy-naïve Burmese entering travelers at Dehong ports in Yunnan, China
by: Qicai Xuan, et al.
Published: (2018-05-01)

High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients
by: Inês Bártolo, et al.
Published: (2022-11-01)

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China
by: Yu F, et al.
Published: (2022-03-01)

Antiretroviral drug resistance among U.S. veterans living with human immunodeficiency virus 1
by: Rahul Mahapatra, et al.
Published: (2019-03-01)

The Many Faces of Immune Activation in HIV-1 Infection: A Multifactorial Interconnection
by: Laura Mazzuti, et al.
Published: (2023-01-01)

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
by: Kaiming Tao, et al.
Published: (2023-09-01)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
by: Eva Wolf, et al.
Published: (2021-09-01)